Key facts
- Notable investors include Fresh.Fund, Good Company (Israel).
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for ProtOS
- ·The full record, as it builds
Funding rounds
No funding rounds for ProtOS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ProtOS
Developer of an AI-first protein research and development platform designed to create biotherapeutics to treat undruggable diseases. The company's platform uses proprietary AI models and structural biology to design de novo AI-proteins and create novel biotherapeutics that are highly specific and effective in degrading previously undruggable pathways by interacting with proteins of interest beyond the reach of small molecules and antibodies, enabling clients to get significant advantages over existing PROTAC and molecular glue approaches.
- Sector
- Healthcare
- HQ
- Jerusalem, Israel
- Founded
- 2023
- Employees
- 4
- Website
- protos.bio/
- Ownership
- Privately Held (backing)
ProtOS doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ProtOS shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ProtOS in its N-PORT filings yet. We sweep new filings monthly.